Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency
This trial is active, not recruiting.
|Start date||January 2015|
|End date||December 2015|
|Trial size||40 participants|
|Trial identifier||NCT02321865, NPC-02-5|
The objective of this study is to check the dose control method of NPC-02 and the holding effect for the target serum zinc concentration in patients with zinc deficiency.
|Intervention model||single group assignment|
The ratio of the patients who could maintain target serum zinc concentration
time frame: approx. 12-24 weeks
Male or female participants of any age.
Inclusion Criteria: - The serum zinc concentrations are under the nomal level before registration - Able to taking a tablet Exclusion Criteria: 1. Heavy hepatitis 2. Malignant tumor 3. Severe heart disease, hematological disorder, kidney disease and pancreatic disease, etc. 4. The serum albumin under 2.8 g/dL 5. Patient of allergy and hyperesthesia to zinc containing medicine manufacturing (including supplement) 6. Patient who was taking a medicine including the zinc (including supplement) within 12 weeks before registration 7. Pregnant, suspected pregnant, lactating, patients who wish to have a child 8. Patient who participated in other clinical trials within 12 weeks before registration 9. Unsuitable as a target of this clinical trial judged by doctor
|Official title||Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency|
Call for more information